GLUE Monte Rosa Therapeutics Inc

Price (delayed)

$17.36

Market cap

$1.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$1.34B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23
Highlights
The equity has surged by 124% since the previous quarter and by 90% year-on-year
The quick ratio has surged by 70% year-on-year and by 55% since the previous quarter
Monte Rosa Therapeutics's revenue has shrunk by 73% YoY and by 65% QoQ
The gross profit has dropped by 73% year-on-year and by 65% since the previous quarter

Key stats

What are the main financial stats of GLUE

GLUE stock price

How has the Monte Rosa Therapeutics stock price performed over time
Intraday
-1.31%
1 week
-10.47%
1 month
-11.29%
1 year
276.57%
YTD
10.71%
QTD
5.53%

Financial performance

How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$42.95M
Gross profit
$42.95M
Operating income
-$148.28M
Net income
-$130.01M
Gross margin
100%
Net margin
-302.7%
The operating income has dropped by 174% since the previous quarter
Monte Rosa Therapeutics's revenue has shrunk by 73% YoY and by 65% QoQ
The gross profit has dropped by 73% year-on-year and by 65% since the previous quarter

Price vs fundamentals

How does GLUE's price correlate with its fundamentals

Growth

What is Monte Rosa Therapeutics's growth rate over time

Valuation

What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
2.66
P/S
40.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.22
The equity has surged by 124% since the previous quarter and by 90% year-on-year
GLUE's P/B is 42% above its 5-year quarterly average of 1.9 and 13% above its last 4 quarters average of 2.4
Monte Rosa Therapeutics's revenue has shrunk by 73% YoY and by 65% QoQ

Efficiency

How efficient is Monte Rosa Therapeutics business performance
Monte Rosa Therapeutics's ROA has plunged by 178% from the previous quarter
GLUE's ROE has dropped by 172% since the previous quarter
The ROIC has plunged by 170% from the previous quarter

Dividends

What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLUE.

Financial health

How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets has soared by 87% year-on-year and by 64% since the previous quarter
The total liabilities has surged by 82% year-on-year
The debt is 93% smaller than the equity
The equity has surged by 124% since the previous quarter and by 90% year-on-year
The debt to equity has plunged by 59% from the previous quarter and by 53% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.